Lista de obras - Leandro Cerchietti - Dominio Público Uruguay

<i>BCL10</i> Mutations Define Distinct Dependencies Guiding Precision Therapy for DLBCL

artículo científico publicado en 2022

A Novel JAK1 Mutant Breast Implant-Associated Anaplastic Large Cell Lymphoma Patient-Derived Xenograft Fostering Pre-Clinical Discoveries

scientific article published on 17 June 2020

A Small-Molecule Inhibitor of BCL6 Kills DLBCL Cells In Vitro and In Vivo

artículo científico publicado en 2010

A hybrid mechanism of action for BCL6 in B cells defined by formation of functionally distinct complexes at enhancers and promoters

artículo científico publicado en 2013

A novel patient-derived tumorgraft model with TRAF1-ALK anaplastic large-cell lymphoma translocation

artículo científico publicado en 2014

A peptomimetic inhibitor of BCL6 with potent antilymphoma effects in vitro and in vivo

artículo científico publicado en 2008

A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6-dependent B cell lymphomas

artículo científico publicado en 2009

Aberration in DNA methylation in B-cell lymphomas has a complex origin and increases with disease severity

artículo científico publicado en 2013

Affinity purification probes of potential use to investigate the endogenous Hsp70 interactome in cancer

artículo científico publicado en 2014

Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90

artículo científico publicado en 2011

Authors' Reply

Authors’ Reply

Award Winner in the Young Investigator Category, 2017 Society for Biomaterials Annual Meeting and Exposition, Minneapolis, MN, April 05-08, 2017: Lymph node stiffness-mimicking hydrogels regulate human B-cell lymphoma growth and cell surface recepto

artículo científico publicado en 2017

BCL6 Antagonizes NOTCH2 to Maintain Survival of Human Follicular Lymphoma Cells

artículo científico publicado en 2017

BCL6 enables Ph+ acute lymphoblastic leukaemia cells to survive BCR-ABL1 kinase inhibition

artículo científico publicado en 2011

BCL6 is critical for the development of a diverse primary B cell repertoire

artículo científico publicado en 2010

BCL6 repression of EP300 in human diffuse large B cell lymphoma cells provides a basis for rational combinatorial therapy

artículo científico publicado en 2010

BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemia

artículo científico publicado en 2011

Clinical and Biological Subtypes of B-cell Lymphoma Revealed by Microenvironmental Signatures

publication published on 04 February 2021

Combination Therapy Targeting BCL6 and Phospho-STAT3 Defeats Intratumor Heterogeneity in a Subset of Non-Small Cell Lung Cancers

artículo científico publicado en 2017

Combinatorial epigenetic therapy in diffuse large B cell lymphoma pre-clinical models and patients

artículo científico publicado en 2016

Combinatorial targeting of nuclear export and translation of RNA inhibits aggressive B-cell lymphomas

artículo científico publicado en 2015

Continuous hyperfractionated accelerated radiation therapy week-end less in combination with neoadjuvant chemotherapy for the treatment of stage III non-small-cell lung cancer

artículo científico publicado en 2007

DNA Methylation-Based Biomarkers.

artículo científico publicado en 2017

DNA methylation signatures define molecular subtypes of diffuse large B-cell lymphoma

artículo científico publicado en 2010

DNA methyltransferase 1 and DNA methylation patterning contribute to germinal center B-cell differentiation

artículo científico publicado en 2011

Double-blinded, placebo-controlled trial on intravenous l-alanyl-l-glutamine in the incidence of oral mucositis following chemoradiotherapy in patients with head-and-neck cancer

scientific article published on 09 June 2006

EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation

artículo científico publicado en 2013

Effective Combination Therapies for B-cell Lymphoma Predicted by a Virtual Disease Model

artículo científico publicado en 2017

Epigenomic evolution in diffuse large B-cell lymphomas

artículo científico publicado en 2015

Ex vivo engineered immune organoids for controlled germinal center reactions

artículo científico publicado en 2015

High affinity and covalent-binding microtubule stabilizing agents show activity in chemotherapy-resistant acute myeloid leukemia cells

artículo científico publicado en 2015

Histone deacetylase inhibitor treatment induces 'BRCAness' and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells

artículo científico publicado en 2014

Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models

scholarly article

Hsp90 is a viable therapeutic target in the treatment of KSHV-associated primary effusion lymphoma.

artículo científico publicado en 2010

Imatinib disrupts lymphoma angiogenesis by targeting vascular pericytes

artículo científico publicado en 2013

Increased protein processing gene signature in HDACi-resistant cells predicts response to proteasome inhibitors.

artículo científico publicado en 2016

Inhibition of anaplastic lymphoma kinase (ALK) activity provides a therapeutic approach for CLTC-ALK-positive human diffuse large B cell lymphomas

artículo científico publicado en 2011

Inhibition of tumor progression and paraneoplastic syndrome development in a murine lung adenocarcinoma by medroxyprogesterone acetate and indomethacin

artículo científico publicado en 2006

Integrin αvβ3 acting as membrane receptor for thyroid hormones mediates angiogenesis in malignant T cells

artículo científico publicado en 2014

Integrin-specific hydrogels as adaptable tumor organoids for malignant B and T cells

artículo científico publicado en 2015

Kaiso-deficient mice show resistance to intestinal cancer

artículo científico publicado en 2006

MALT1 small molecule inhibitors specifically suppress ABC-DLBCL in vitro and in vivo

artículo científico publicado en 2012

Mechanism-based epigenetic chemosensitization therapy of diffuse large B-cell lymphoma

artículo científico publicado en 2013

Methods for sample acquisition and processing of serial blood and tumor biopsies for multicenter diffuse large B-cell lymphoma clinical trials

artículo científico publicado en 2014

Microscale Bioadhesive Hydrogel Arrays for Cell Engineering Applications

artículo científico publicado en 2014

Midazolam as adjunct therapy to morphine in the alleviation of severe dyspnea perception in patients with advanced cancer.

artículo científico publicado en 2006

Mir-592 regulates the induction and cell death-promoting activity of p75NTR in neuronal ischemic injury

artículo científico publicado en 2014

Morphine mouthwashes for painful mucositis

scientific article published on 15 August 2006

Morphine versus midazolam as upfront therapy to control dyspnea perception in cancer patients while its underlying cause is sought or treated

artículo científico publicado en 2010

Oncogenic HSP90 Facilitates Metabolic Alterations in Aggressive B-cell Lymphomas

artículo científico publicado en 2021

Personalized Epigenetic Therapy—Chemosensitivity Testing

Pharmacoproteomics identifies combinatorial therapy targets for diffuse large B cell lymphoma

artículo científico publicado en 2015

Phase I/II study of selective cyclooxygenase-2 inhibitor celecoxib as a radiation sensitizer in patients with unresectable brain metastases.

artículo científico publicado en 2005

Potential utility of the peripheral analgesic properties of morphine in stomatitis-related pain: a pilot study.

artículo científico publicado en 2003

Pre-B cell receptor-mediated activation of BCL6 induces pre-B cell quiescence through transcriptional repression of MYC.

artículo científico publicado en 2011

Progesterone receptor activation downregulates GATA3 by transcriptional repression and increased protein turnover promoting breast tumor growth

artículo científico publicado en 2014

Rationally designed BCL6 inhibitors target activated B cell diffuse large B cell lymphoma

artículo científico publicado en 2016

Response to second-line therapy defines the potential for cure in patients with recurrent diffuse large B-cell lymphoma: implications for the development of novel therapeutic strategies

artículo científico publicado en 2010

Selective targeting of BCL6 induces oncogene addiction switching to BCL2 in B-cell lymphoma

artículo científico publicado en 2015

Sequential transcription factor targeting for diffuse large B-cell lymphomas

artículo científico publicado en 2008

Specific peptide interference reveals BCL6 transcriptional and oncogenic mechanisms in B-cell lymphoma cells.

artículo científico publicado en 2004

Structure of a BCOR Corepressor Peptide in Complex with the BCL6 BTB Domain Dimer

artículo científico publicado en 2008

THZ1 targeting CDK7 suppresses STAT transcriptional activity and sensitizes T-cell lymphomas to BCL2 inhibitors

artículo científico publicado en 2017

Targeting BCL6 in diffuse large B-cell lymphoma: what does this mean for the future treatment?

artículo científico publicado en 2013

Targeting the Hsp90-associated viral oncoproteome in gammaherpesvirus-associated malignancies

artículo científico publicado en 2013

Targeting the epigenome and other new strategies in diffuse large B-cell lymphoma: beyond R-CHOP.

artículo científico publicado en 2013

The BCL6 transcriptional program features repression of multiple oncogenes in primary B cells and is deregulated in DLBCL.

artículo científico publicado en 2009

The Bcl6-SMRT/NCoR cistrome represses inflammation to attenuate atherosclerosis

artículo científico publicado en 2012

The eIF4E inhibitor ribavirin as a potential antilymphoma therapeutic: early clinical data

artículo científico publicado en 2017

The epichaperome is an integrated chaperome network that facilitates tumour survival

artículo científico publicado en 2016

The eukaryotic translation initiation factor eIF4E elevates steady-state m7G capping of coding and noncoding transcripts

artículo científico publicado en 2020

The metabolic adaptation evoked by arginine enhances the effect of radiation in brain metastases

artículo científico publicado en 2021

The metabolism of lymphomas

artículo científico

The sonic hedgehog factor GLI1 imparts drug resistance through inducible glucuronidation

artículo científico publicado en 2014

The transcriptional modulator BCL6 as a molecular target for breast cancer therapy

artículo científico publicado en 2014

Therapeutic efficacy of the bromodomain inhibitor OTX015/MK-8628 in ALK-positive anaplastic large cell lymphoma: an alternative modality to overcome resistant phenotypes

artículo científico

Therapeutic implication of concomitant chromosomal aberrations in patients with aggressive B-cell lymphomas

artículo científico publicado en 2016

Transcriptional signature with differential expression of BCL6 target genes accurately identifies BCL6-dependent diffuse large B cell lymphomas.

artículo científico publicado en 2007

Variational autoencoders learn transferrable representations of metabolomics data

artículo científico publicado en 2022

Lista de obras de Leandro Cerchietti

<i>BCL10</i> Mutations Define Distinct Dependencies Guiding Precision Therapy for DLBCL

A Novel JAK1 Mutant Breast Implant-Associated Anaplastic Large Cell Lymphoma Patient-Derived Xenograft Fostering Pre-Clinical Discoveries

A Small-Molecule Inhibitor of BCL6 Kills DLBCL Cells In Vitro and In Vivo

A hybrid mechanism of action for BCL6 in B cells defined by formation of functionally distinct complexes at enhancers and promoters

A novel patient-derived tumorgraft model with TRAF1-ALK anaplastic large-cell lymphoma translocation

A peptomimetic inhibitor of BCL6 with potent antilymphoma effects in vitro and in vivo

A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6-dependent B cell lymphomas

Aberration in DNA methylation in B-cell lymphomas has a complex origin and increases with disease severity

Affinity purification probes of potential use to investigate the endogenous Hsp70 interactome in cancer

Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90

Authors' Reply

Authors’ Reply

Award Winner in the Young Investigator Category, 2017 Society for Biomaterials Annual Meeting and Exposition, Minneapolis, MN, April 05-08, 2017: Lymph node stiffness-mimicking hydrogels regulate human B-cell lymphoma growth and cell surface recepto

BCL6 Antagonizes NOTCH2 to Maintain Survival of Human Follicular Lymphoma Cells

BCL6 enables Ph+ acute lymphoblastic leukaemia cells to survive BCR-ABL1 kinase inhibition

BCL6 is critical for the development of a diverse primary B cell repertoire

BCL6 repression of EP300 in human diffuse large B cell lymphoma cells provides a basis for rational combinatorial therapy

BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemia

Clinical and Biological Subtypes of B-cell Lymphoma Revealed by Microenvironmental Signatures

Combination Therapy Targeting BCL6 and Phospho-STAT3 Defeats Intratumor Heterogeneity in a Subset of Non-Small Cell Lung Cancers

Combinatorial epigenetic therapy in diffuse large B cell lymphoma pre-clinical models and patients

Combinatorial targeting of nuclear export and translation of RNA inhibits aggressive B-cell lymphomas

Continuous hyperfractionated accelerated radiation therapy week-end less in combination with neoadjuvant chemotherapy for the treatment of stage III non-small-cell lung cancer

DNA Methylation-Based Biomarkers.

DNA methylation signatures define molecular subtypes of diffuse large B-cell lymphoma

DNA methyltransferase 1 and DNA methylation patterning contribute to germinal center B-cell differentiation

Double-blinded, placebo-controlled trial on intravenous l-alanyl-l-glutamine in the incidence of oral mucositis following chemoradiotherapy in patients with head-and-neck cancer

EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation

Effective Combination Therapies for B-cell Lymphoma Predicted by a Virtual Disease Model

Epigenomic evolution in diffuse large B-cell lymphomas

Ex vivo engineered immune organoids for controlled germinal center reactions

High affinity and covalent-binding microtubule stabilizing agents show activity in chemotherapy-resistant acute myeloid leukemia cells

Histone deacetylase inhibitor treatment induces 'BRCAness' and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells

Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models

Hsp90 is a viable therapeutic target in the treatment of KSHV-associated primary effusion lymphoma.

Imatinib disrupts lymphoma angiogenesis by targeting vascular pericytes

Increased protein processing gene signature in HDACi-resistant cells predicts response to proteasome inhibitors.

Inhibition of anaplastic lymphoma kinase (ALK) activity provides a therapeutic approach for CLTC-ALK-positive human diffuse large B cell lymphomas

Inhibition of tumor progression and paraneoplastic syndrome development in a murine lung adenocarcinoma by medroxyprogesterone acetate and indomethacin

Integrin αvβ3 acting as membrane receptor for thyroid hormones mediates angiogenesis in malignant T cells

Integrin-specific hydrogels as adaptable tumor organoids for malignant B and T cells

Kaiso-deficient mice show resistance to intestinal cancer

MALT1 small molecule inhibitors specifically suppress ABC-DLBCL in vitro and in vivo

Mechanism-based epigenetic chemosensitization therapy of diffuse large B-cell lymphoma

Methods for sample acquisition and processing of serial blood and tumor biopsies for multicenter diffuse large B-cell lymphoma clinical trials

Microscale Bioadhesive Hydrogel Arrays for Cell Engineering Applications

Midazolam as adjunct therapy to morphine in the alleviation of severe dyspnea perception in patients with advanced cancer.

Mir-592 regulates the induction and cell death-promoting activity of p75NTR in neuronal ischemic injury

Morphine mouthwashes for painful mucositis

Morphine versus midazolam as upfront therapy to control dyspnea perception in cancer patients while its underlying cause is sought or treated

Oncogenic HSP90 Facilitates Metabolic Alterations in Aggressive B-cell Lymphomas

Personalized Epigenetic Therapy—Chemosensitivity Testing

Pharmacoproteomics identifies combinatorial therapy targets for diffuse large B cell lymphoma

Phase I/II study of selective cyclooxygenase-2 inhibitor celecoxib as a radiation sensitizer in patients with unresectable brain metastases.

Potential utility of the peripheral analgesic properties of morphine in stomatitis-related pain: a pilot study.

Pre-B cell receptor-mediated activation of BCL6 induces pre-B cell quiescence through transcriptional repression of MYC.

Progesterone receptor activation downregulates GATA3 by transcriptional repression and increased protein turnover promoting breast tumor growth

Rationally designed BCL6 inhibitors target activated B cell diffuse large B cell lymphoma

Response to second-line therapy defines the potential for cure in patients with recurrent diffuse large B-cell lymphoma: implications for the development of novel therapeutic strategies

Selective targeting of BCL6 induces oncogene addiction switching to BCL2 in B-cell lymphoma

Sequential transcription factor targeting for diffuse large B-cell lymphomas

Specific peptide interference reveals BCL6 transcriptional and oncogenic mechanisms in B-cell lymphoma cells.

Structure of a BCOR Corepressor Peptide in Complex with the BCL6 BTB Domain Dimer

THZ1 targeting CDK7 suppresses STAT transcriptional activity and sensitizes T-cell lymphomas to BCL2 inhibitors

Targeting BCL6 in diffuse large B-cell lymphoma: what does this mean for the future treatment?

Targeting the Hsp90-associated viral oncoproteome in gammaherpesvirus-associated malignancies

Targeting the epigenome and other new strategies in diffuse large B-cell lymphoma: beyond R-CHOP.

The BCL6 transcriptional program features repression of multiple oncogenes in primary B cells and is deregulated in DLBCL.

The Bcl6-SMRT/NCoR cistrome represses inflammation to attenuate atherosclerosis

The eIF4E inhibitor ribavirin as a potential antilymphoma therapeutic: early clinical data

The epichaperome is an integrated chaperome network that facilitates tumour survival

The eukaryotic translation initiation factor eIF4E elevates steady-state m7G capping of coding and noncoding transcripts

The metabolic adaptation evoked by arginine enhances the effect of radiation in brain metastases

The metabolism of lymphomas

The sonic hedgehog factor GLI1 imparts drug resistance through inducible glucuronidation

The transcriptional modulator BCL6 as a molecular target for breast cancer therapy

Therapeutic efficacy of the bromodomain inhibitor OTX015/MK-8628 in ALK-positive anaplastic large cell lymphoma: an alternative modality to overcome resistant phenotypes

Therapeutic implication of concomitant chromosomal aberrations in patients with aggressive B-cell lymphomas

Transcriptional signature with differential expression of BCL6 target genes accurately identifies BCL6-dependent diffuse large B cell lymphomas.